Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials
| العنوان: | Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials |
|---|---|
| المؤلفون: | Shawn X Sun, Peter M.A. Calverley, Stephen I. Rennard, Udo M Goehring, Stavros Tourkodimitris, Dirk Bredenbröker, Paul Rowe |
| المصدر: | International Journal of Chronic Obstructive Pulmonary Disease |
| بيانات النشر: | Dove Medical Press, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Gerontology, Cyclopropanes, Male, Time Factors, Aminopyridines, International Journal of Chronic Obstructive Pulmonary Disease, Severe chronic obstructive pulmonary disease, Severity of Illness Index, subgroup analyses, Pulmonary Disease, Chronic Obstructive, Risk Factors, Phosphodiesterase 4 Inhibitor, Forced Expiratory Volume, Osteopathic physicians, Medicine, Humans, In patient, phosphodiesterase-4 inhibitor, Lung, Original Research, Aged, Randomized Controlled Trials as Topic, business.industry, Vantage point, breathlessness, Continuing education, lung function, General Medicine, Recovery of Function, Middle Aged, Management, Clinical trial, Pooled analysis, Dyspnea, Treatment Outcome, Benzamides, Female, Phosphodiesterase 4 Inhibitors, business |
| الوصف: | Stephen I Rennard,1 Shawn X Sun,2 Stavros Tourkodimitris,2 Paul Rowe,2 Udo M Goehring,3 Dirk Bredenbröker,3 Peter M A Calverley4 1Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE, USA; 2Forest Research Institute, Jersey City, NJ, USA; 3Takeda Pharmaceuticals International GmbH, Zurich, Switzerland; 4Department of Clinical Science, University of Liverpool, Liverpool, UK Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD. Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted. Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P |
| وصف الملف: | text/html |
| اللغة: | English |
| تدمد: | 1178-2005 1176-9106 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e26fe28b194c9a49fa4e524ca6eab7c http://europepmc.org/articles/PMC4075954 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3e26fe28b194c9a49fa4e524ca6eab7c |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 11782005 11769106 |
|---|